coin-img-ETHETH+0.99%coin-img-BTCBTC+0.98%coin-img-SOLSOL+1.18%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX-61.04%coin-img-XRPXRP+0.38%coin-img-HYPEHYPE-2.96%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.99%coin-img-BTCBTC+0.98%coin-img-SOLSOL+1.18%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX-61.04%coin-img-XRPXRP+0.38%coin-img-HYPEHYPE-2.96%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.99%coin-img-BTCBTC+0.98%coin-img-SOLSOL+1.18%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX-61.04%coin-img-XRPXRP+0.38%coin-img-HYPEHYPE-2.96%coin-img-TRXTRX+0.61%coin-img-ETHETH+0.99%coin-img-BTCBTC+0.98%coin-img-SOLSOL+1.18%coin-img-USDCUSDC+0.01%coin-img-UBOXUBOX-61.04%coin-img-XRPXRP+0.38%coin-img-HYPEHYPE-2.96%coin-img-TRXTRX+0.61%
user-avatar
Reuters

Magnum Ice Cream beats earnings estimates as adjusted EBITDA rises to €880 million in Q2 2026

AI Market Summary
Magnum Ice Cream's Q2 2026 results beat consensus as supply-chain and corporate-transformation cost cuts lifted adjusted EBITDA, while Ben & Jerry's posted strong North America growth and market-share gains. The beat supports near-term confidence ahead of its planned Amsterdam listing, framed as a test of resilience amid shifting consumer preferences linked to GLP-1 weight-loss drugs and U.S. health-policy messaging. Broader market impact appears limited.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.50%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Magnum Ice Cream reported stronger-than-expected results for the second quarter of 2026, with adjusted EBITDA rising to €880 million, up 3.2% year on year. The company attributed the improvement to cost cuts from supply-chain initiatives and a corporate transformation. Ben & Jerry’s sales in North America increased 9.2% from a year earlier. Magnum is moving ahead with plans for an Amsterdam listing, seen as a key test of its resilience as GLP-1 weight-loss drugs and the U.S. “Make America Healthy Again” policy shift reshape consumer demand.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.